Eur Rev Med Pharmacol Sci 2020; 24 (20): 10383-10390
DOI: 10.26355/eurrev_202010_23388

MiR-127-3p inhibits proliferation of ovarian cancer in rats through down-regulating MAPK4

S.-Y. Du, X.-X. Huang, N.-M. Li, C.-Y. Lv, C.-H. Lv, M.-L. Wei, Z. Gao, Y.-P. Zhang

Department of Obstetrics and Gynecology, Jinan City People’s Hospital, Jinan, China. 851256@qq.com


OBJECTIVE: To reveal the anti-tumor effect of micro ribonucleic acid (miR)-127-3p on epithelial ovarian cancer (EOC).

PATIENTS AND METHODS: The expression of miR-127-3p in 7 kinds of EOC cell lines and 10 cases of clinical samples of EOC patients was detected via quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). OVCAR-3 and Caov-3 cell lines were transfected with lentiviruses to overexpress endogenous miR-127-3p. Then, the anti-tumor effect of miR-127-3p on EOC cells was explored through the in vitro cell proliferation assay, bufalin sensitivity assay, wound healing assay, and invasion assay. In addition, whether the mitogen-activated protein kinase 4 (MAPK4) gene is a downstream target of miR-127-3p in EOC was verified via Dual-Luciferase reporter assay and qRT-PCR. The involvement of MAPK4 in regulating phenotypes of OVCAR-3 and Caov-3 cells was finally explored.

RESULTS: MiR-127-3p was downregulated in both EOC cell lines and EOC tissues (p<0.05). After lentivirus-mediated overexpression of miR-127-3p, in vitro proliferation and invasion of EOC cells were inhibited, and the sensitivity to bufalin was enhanced (p<0.05). MiR-127-3p directly regulated MAPK4 gene in EOC. Moreover, the upregulation of MAPK4 inhibited the anti-tumor effect of miR-127-3p on EOC, manifested as the remarkably enhanced cell proliferation and migration (p<0.05), and the weakened sensitivity to bufalin (p<0.01).

CONCLUSIONS: MiR-127-3p exerts an inhibitory effect on EOC cells via regulating MAPK4 level.

Free PDF Download

To cite this article

S.-Y. Du, X.-X. Huang, N.-M. Li, C.-Y. Lv, C.-H. Lv, M.-L. Wei, Z. Gao, Y.-P. Zhang
MiR-127-3p inhibits proliferation of ovarian cancer in rats through down-regulating MAPK4

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 20
Pages: 10383-10390
DOI: 10.26355/eurrev_202010_23388